Company Description
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions.
It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions.
It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment.
In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation.
Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.
| Country | United States |
| Founded | 1960 |
| IPO Date | Aug 4, 2000 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 11,085 |
| CEO | Frank Laukien |
Contact Details
Address: 40 Manning Road Billerica, Massachusetts 01821 United States | |
| Phone | 978 663 3660 |
| Website | bruker.com |
Stock Details
| Ticker Symbol | BRKR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001109354 |
| CUSIP Number | 116794108 |
| ISIN Number | US1167941087 |
| Employer ID | 04-3110160 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Burkhard Prause Ph.D. | President and Chief Executive Officer of Bruker Energy and Supercon Technologies, Inc. |
| Dr. Frank H. Laukien Ph.D. | Chairman, Chief Executive Officer and President |
| Gerald N. Herman CPA | Executive Vice President and Chief Financial Officer |
| Dr. Mark R. Munch Ph.D. | Corporate Executive Vice President and President of Bruker Nano Group and Corporate |
| Juergen Srega | President of Bruker CALID Group and Bruker Daltonics Division |
| Dr. Falko Busse Ph.D. | President of Bruker BioSpin Group |
| Thomas Bures | Chief Accounting Officer |
| J. Brent Alldredge J.D. | Senior Vice President, General Counsel, Secretary and Global Head of Compliance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 13, 2026 | 144 | Filing |
| Mar 6, 2026 | SCHEDULE 13G/A | Filing |
| Feb 27, 2026 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |
| Feb 27, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 27, 2026 | 10-K | Annual Report |
| Feb 20, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 13, 2026 | 144 | Filing |
| Feb 12, 2026 | 8-K | Current Report |